Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) is set to participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference on August 9, 2022, at 3:00 p.m. PT. The event will feature a fireside chat with company management, accessible via a live and archived webcast on their investor relations website.

Absci is focused on drug and target discovery, leveraging deep learning AI and synthetic biology to enhance protein therapeutic potential. Their Integrated Drug Creation™ Platform enables efficient identification and development of novel biotherapeutics.

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.

Absci management is scheduled to participate in a fireside chat on Tuesday, August 9^th at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Absci Investor Contact

investors@absci.com

Absci Media Contact

press@absci.com

FAQ

When is Absci Corporation participating in the UBS Genomics 2.0 and MedTech Innovations Summit Conference?

Absci Corporation will participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference on August 9, 2022, at 3:00 p.m. Pacific Time.

How can I access the webcast for Absci's presentation at the UBS Conference?

The webcast for Absci's presentation can be accessed live and archived on their investor relations website.

What is Absci Corporation's focus in the biotechnology sector?

Absci Corporation specializes in drug and target discovery, utilizing deep learning AI and synthetic biology to optimize protein-based therapies.

What technology does Absci use for drug discovery?

Absci employs its Integrated Drug Creation™ Platform to identify novel drug targets and develop biotherapeutic candidates efficiently.

What is the stock symbol for Absci Corporation?

The stock symbol for Absci Corporation is ABSI.